Aastrom Biosciences Inc Stock price Nasdaq
Equities
US00253U4040
Pharmaceuticals
Financials (USD)
Sales 2024 * | 239M | Sales 2025 * | 299M | Capitalization | 2.51B |
---|---|---|---|---|---|
Net income 2024 * | 4M | Net income 2025 * | 25M | EV / Sales 2024 * | 10.5 x |
Net cash position 2024 * | - | Net cash position 2025 * | - | EV / Sales 2025 * | 8.4 x |
P/E ratio 2024 * |
650
x | P/E ratio 2025 * |
107
x | Employees | - |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99.17% |
Latest transcript on Aastrom Biosciences Inc
Managers | Title | Age | Since |
---|---|---|---|
Chief Executive Officer | 60 | 13-02-28 | |
Joseph Mara
DFI | Director of Finance/CFO | 49 | 21-01-24 |
Michael Halpin
COO | Chief Operating Officer | 62 | 17-04-09 |
Members of the board | Title | Age | Since |
---|---|---|---|
Paul Wotton
BRD | Director/Board Member | 63 | 15-01-05 |
Kevin McLaughlin
BRD | Director/Board Member | 67 | 15-01-05 |
Robert Zerbe
CHM | Chairman | 73 | 06-01-15 |
1st Jan change | Capi. | |
---|---|---|
+0.44% | 90.78B | |
+9.61% | 43.96B | |
-16.67% | 31.34B | |
+44.99% | 23.45B | |
-9.42% | 16.48B | |
-25.92% | 15.03B | |
-9.27% | 12.79B | |
-7.57% | 12.19B | |
+0.07% | 8.5B |